Merck & Company Inc (MRK)vsPluri Inc. (PLUR)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
PLUR
Pluri Inc.
$3.42
+1.48%
HEALTHCARE · Cap: $36.85M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4855090% more annual revenue ($65.01B vs $1.34M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PLUR
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for PLUR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1022.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PLUR
PLUR has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PLUR
The primary concerns for PLUR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
PLUR carries more volatility with a beta of 0.72 — expect wider price swings.
PLUR is growing revenue faster at 7.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 17/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Pluri Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Pluri Inc. is an innovative biotechnology company specializing in regenerative medicine and immunotherapy, focused on developing advanced cell-based therapies for oncology and degenerative diseases. Utilizing its proprietary technology platform, Pluri aims to improve patient outcomes and drive growth through a promising pipeline of therapeutics and strategic collaborations with industry partners. By harnessing the potential of human cells, the company is positioning itself as a key player in the biotechnology sector, committed to delivering transformative solutions that address critical unmet medical needs in the evolving healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?